Amgen - AMGN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $296.95
Forecasted Upside: 10.24%
Number of Analysts: 19
Breakdown:
0 Sell Ratings
9 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$269.38 As of 04/25/2024 01:00 AM ET

▼ -3.63 (-1.33%)

1 month | 3 months | 12 months

Get New Amgen Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMGN

^$296.95

▲ +10.24% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $296.95, with a high forecast of $360.00 and a low forecast of $200.00. The average price target represents a 10.24% upside from the last price of $269.38.

Current Consensus is Moderate Buy

The current consensus among 19 polled investment analysts is to moderate buy stock in Amgen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
10 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$314.00 ➝ $284.00	Low
4/17/2024	TD Cowen	Lower Target	Buy ➝ Buy	$370.00 ➝ $360.00	Low
4/12/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$320.00	Low
4/3/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$329.00	Low
3/28/2024	Raymond James	Initiated Coverage	Market Perform		N/A
2/7/2024	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$281.00 ➝ $278.00	Low
2/7/2024	Leerink Partnrs	Downgrade	Outperform ➝ Market Perform		Low
2/7/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$303.00 ➝ $329.00	Low
2/7/2024	The Goldman Sachs Group	Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	Low
2/7/2024	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$324.00 ➝ $318.00	Low
2/1/2024	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$350.00	Low
1/29/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$315.00 ➝ $314.00	Low
12/21/2023	Daiwa Capital Markets	Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	Low
12/19/2023	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$286.00 ➝ $326.00	Low
12/12/2023	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$256.00 ➝ $300.00	Low
11/29/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$320.00	Low
11/9/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$240.00	Low
11/2/2023	UBS Group	Lower Target	Neutral ➝ Neutral	$272.00 ➝ $268.00	Low
11/2/2023	Truist Financial	Upgrade	Hold ➝ Buy	$260.00 ➝ $320.00	Low
11/1/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$253.00 ➝ $256.00	Low
11/1/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$300.00 ➝ $291.00	Low
10/20/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$290.00 ➝ $300.00	Low
10/20/2023	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Neutral	$270.00	Low
10/17/2023	Argus	Boost Target	Buy ➝ Buy	$280.00 ➝ $310.00	Low
10/17/2023	Morgan Stanley	Reiterated Rating	Equal Weight	$300.00	Low
10/12/2023	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$310.00	Low
10/12/2023	Wells Fargo & Company	Boost Target		$265.00 ➝ $320.00	Low
10/11/2023	Leerink Partnrs	Upgrade	Market Perform ➝ Outperform		Low
10/11/2023	Bank of America	Initiated Coverage	Neutral	$290.00	Low
10/11/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$267.00 ➝ $318.00	Low
10/9/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$280.00 ➝ $290.00	Low
10/2/2023	Barclays	Boost Target		$210.00 ➝ $230.00	Low
9/18/2023	Argus	Boost Target	Buy ➝ Buy	$260.00 ➝ $280.00	Low
9/6/2023	HSBC	Initiated Coverage	Buy	$320.00	Low
9/5/2023	Truist Financial	Reiterated Rating	Hold ➝ Hold	$260.00	Low
8/14/2023	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$275.00 ➝ $310.00	Low
8/14/2023	Mizuho	Boost Target	Neutral ➝ Neutral	$214.00 ➝ $223.00	Low
8/4/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$250.00 ➝ $253.00	Low
7/25/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$280.00	Low
7/12/2023	Credit Suisse Group	Lower Target		$220.00 ➝ $200.00	Low
7/11/2023	Barclays	Lower Target		$225.00 ➝ $210.00	Low
7/7/2023	Jefferies Financial Group	Lower Target		$325.00 ➝ $275.00	Low
6/26/2023	Argus	Lower Target		$270.00 ➝ $260.00	Low
5/3/2023	Mizuho	Boost Target		$208.00 ➝ $214.00	Low
5/1/2023	Barclays	Lower Target		$227.00 ➝ $225.00	Low
4/28/2023	Piper Sandler	Lower Target		$293.00 ➝ $288.00	Low
4/24/2023	Oppenheimer	Lower Target	Outperform	$292.00 ➝ $290.00	Low
4/14/2023	Barclays	Lower Target	Underweight	$230.00 ➝ $227.00	Low
3/13/2023	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$275.00 ➝ $265.00	Low
2/13/2023	Truist Financial	Lower Target	Buy	$280.00 ➝ $260.00	Low
2/6/2023	Argus	Lower Target		$300.00 ➝ $270.00	Low
2/2/2023	SVB Leerink	Lower Target	Market Perform	$282.00 ➝ $267.00	Low
2/2/2023	SVB Securities	Lower Target		$282.00 ➝ $267.00	Low
2/1/2023	Oppenheimer	Lower Target	Outperform	$312.00 ➝ $294.00	Low
2/1/2023	Royal Bank of Canada	Lower Target	Sector Perform	$268.00 ➝ $258.00	Low
2/1/2023	Wells Fargo & Company	Lower Target	Equal Weight	$285.00 ➝ $275.00	Low
2/1/2023	BMO Capital Markets	Lower Target	Market Perform	$276.00 ➝ $253.00	Low
2/1/2023	Cowen	Lower Target	Outperform	$307.00 ➝ $289.00	Low
2/1/2023	Credit Suisse Group	Lower Target	Underperform	$240.00 ➝ $220.00	Low
2/1/2023	Barclays	Lower Target	Underweight	$240.00 ➝ $230.00	Low
1/19/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$299.00 ➝ $293.00	Low
1/18/2023	Barclays	Boost Target	Underweight	$234.00 ➝ $240.00	Low
1/3/2023	Wells Fargo & Company	Boost Target	Equal Weight	$250.00 ➝ $285.00	Low
12/22/2022	SVB Leerink	Boost Target	Market Perform	$256.00 ➝ $282.00	Low
12/12/2022	Piper Sandler	Boost Target	Overweight	$297.00 ➝ $299.00	Low
12/6/2022	Oppenheimer	Boost Target	Outperform	$300.00 ➝ $310.00	Low
12/5/2022	Piper Sandler	Boost Target		$278.00 ➝ $297.00	Low
11/17/2022	Credit Suisse Group	Initiated Coverage	Underperform	$240.00	Low
11/15/2022	Oppenheimer	Boost Target		$300.00	N/A
11/8/2022	Oppenheimer	Boost Target		$290.00 ➝ $300.00	Low
11/8/2022	Truist Financial	Boost Target	Hold ➝ Hold	$266.00 ➝ $280.00	Low
11/4/2022	Royal Bank of Canada	Boost Target	Sector Perform	$235.00 ➝ $240.00	Low
11/4/2022	Morgan Stanley	Boost Target	Overweight	$279.00 ➝ $282.00	Low
11/4/2022	Piper Sandler	Boost Target	Overweight	$265.00 ➝ $278.00	Low
10/31/2022	Barclays	Downgrade	Equal Weight ➝ Underweight	$234.00	Low
10/12/2022	Barclays	Lower Target	Equal Weight	$236.00 ➝ $234.00	Low
10/11/2022	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$257.00 ➝ $279.00	N/A
10/3/2022	Oppenheimer	Reiterated Rating	Outperform	$290.00	Low
9/14/2022	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$290.00	Low
9/13/2022	Robert W. Baird	Reiterated Rating	Underperform	$185.00	Low
9/1/2022	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$290.00	Low
8/10/2022	Oppenheimer	Reiterated Rating	Buy ➝ Buy	$290.00	Low
8/9/2022	Atlantic Securities	Lower Target	Underweight	$190.00 ➝ $182.00	Low
8/5/2022	Piper Sandler	Boost Target	Overweight	$260.00 ➝ $265.00	Low
8/5/2022	Royal Bank of Canada	Boost Target		$224.00 ➝ $236.00	Low
7/15/2022	Morgan Stanley	Boost Target	Equal Weight	$239.00 ➝ $253.00	Low
6/24/2022	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$290.00	Low
6/1/2022	Oppenheimer	Boost Target	Outperform	$285.00 ➝ $290.00	Medium
5/23/2022	SVB Leerink	Initiated Coverage	Market Perform	$256.00	Low
5/10/2022	Mizuho	Boost Target		$202.00 ➝ $208.00	Low
5/3/2022	Oppenheimer	Downgrade	Outperform	$285.00	Low
4/28/2022	BMO Capital Markets	Lower Target		$263.00 ➝ $243.00	Low
4/28/2022	Piper Sandler	Boost Target		$255.00 ➝ $260.00	High
4/12/2022	Morgan Stanley	Lower Target	Equal Weight	$238.00 ➝ $237.00	Low
4/12/2022	Barclays	Boost Target	Equal Weight	$233.00 ➝ $236.00	Low
3/1/2022	Mizuho	Boost Target		$194.00 ➝ $202.00	Low
2/9/2022	Morgan Stanley	Boost Target	Equal Weight	$235.00 ➝ $238.00	Low
2/9/2022	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$266.00 ➝ $280.00	Low
2/9/2022	Oppenheimer	Boost Target	Outperform	$272.00 ➝ $285.00	Medium
2/9/2022	Barclays	Boost Target	Equal Weight	$228.00 ➝ $233.00	Medium
2/9/2022	Wells Fargo & Company	Boost Target	Equal Weight	$210.00 ➝ $250.00	Medium
1/5/2022	Bank of America	Downgrade	Buy ➝ Neutral	$285.00 ➝ $255.00	Low
12/21/2021	Royal Bank of Canada	Boost Target	Sector Perform	$216.00 ➝ $218.00	Low
12/8/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$213.00 ➝ $210.00	Low
12/6/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$258.00	High
11/22/2021	Mizuho	Lower Target	Neutral	$222.00 ➝ $194.00	Medium
11/18/2021	BMO Capital Markets	Initiated Coverage	Market Perform	$228.00	Low
11/3/2021	Royal Bank of Canada	Lower Target	Sector Perform	$217.00 ➝ $216.00	High
11/3/2021	SVB Leerink	Lower Target	Market Perform	$234.00 ➝ $216.00	High
11/3/2021	Barclays	Lower Target	Equal Weight	$230.00 ➝ $228.00	High
11/1/2021	Oppenheimer	Lower Target	Outperform	$277.00 ➝ $272.00	Medium
10/28/2021	Robert W. Baird	Reiterated Rating	Sell		Low
10/12/2021	Morgan Stanley	Lower Target	Equal Weight	$251.00 ➝ $235.00	High
9/23/2021	Daiwa Capital Markets	Downgrade	Outperform ➝ Neutral	$220.00	Low
9/19/2021	SVB Leerink	Initiated Coverage	Hold		Medium
9/17/2021	William Blair	Reiterated Rating	Hold		High
9/10/2021	Mizuho	Initiated Coverage	Hold	$222.00	Low
9/7/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$280.00 ➝ $251.00	High
8/5/2021	Robert W. Baird	Reiterated Rating	Sell		High
8/4/2021	SVB Leerink	Lower Target	Market Perform	$238.00 ➝ $234.00	High
7/28/2021	Robert W. Baird	Reiterated Rating	Sell	$185.00	Low
7/16/2021	Morgan Stanley	Boost Target	Overweight	$278.00 ➝ $280.00	Medium
6/25/2021	Mizuho	Reiterated Rating	Hold	$200.00	Medium
6/7/2021	SVB Leerink	Boost Target	Market Perform	$230.00 ➝ $238.00	Low
6/7/2021	Oppenheimer	Boost Target	Outperform	$272.00 ➝ $277.00	Low
5/31/2021	BMO Capital Markets	Boost Target	Positive ➝ Outperform	$296.00 ➝ $301.00	High
5/17/2021	Oppenheimer	Reiterated Rating	Buy	$270.00	Low
5/4/2021	Atlantic Securities	Reiterated Rating	Neutral ➝ Underweight	$200.00	N/A
5/3/2021	Oppenheimer	Lower Target	Outperform	$275.00 ➝ $265.00	Low
4/29/2021	Robert W. Baird	Reiterated Rating	Sell		Medium
4/29/2021	Evercore ISI	Reiterated Rating	Buy		Medium
4/28/2021	Atlantic Securities	Downgrade	Neutral ➝ Underweight	$200.00	Low
4/28/2021	Credit Suisse Group	Lower Target	Outperform	$265.00 ➝ $259.00	High
4/28/2021	SVB Leerink	Lower Target	Market Perform	$267.00 ➝ $230.00	High
4/28/2021	Royal Bank of Canada	Lower Target	Sector Perform	$220.00 ➝ $217.00	High
4/28/2021	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$215.00	High
4/28/2021	The Goldman Sachs Group	Reiterated Rating	Buy	$290.00	High
4/28/2021	BMO Capital Markets	Lower Target	Outperform	$301.00 ➝ $296.00	High
4/26/2021	Morgan Stanley	Lower Target	Overweight	$281.00 ➝ $278.00	Low
4/19/2021	Morgan Stanley	Boost Target	Overweight	$279.00 ➝ $281.00	Low
4/5/2021	Oppenheimer	Boost Target		$266.00 ➝ $275.00	Low
3/5/2021	Barclays	Lower Target	Equal Weight	$242.00 ➝ $230.00	High
3/5/2021	Morgan Stanley	Boost Target	Overweight	$277.00 ➝ $279.00	High
3/4/2021	JPMorgan Chase & Co.	Set Target	Neutral	$222.00	High
3/4/2021	The Goldman Sachs Group	Set Target	Buy	$277.00	High
3/1/2021	SVB Leerink	Boost Target	Market Perform	$252.00 ➝ $260.00	Low
2/3/2021	Morgan Stanley	Lower Target	Overweight	$285.00 ➝ $277.00	Medium
2/3/2021	Credit Suisse Group	Lower Target	Outperform	$280.00 ➝ $265.00	Medium
2/3/2021	SVB Leerink	Lower Target	Market Perform	$253.00 ➝ $245.00	Medium
2/3/2021	Piper Sandler	Lower Target	Overweight	$280.00 ➝ $260.00	Medium
2/3/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$280.00 ➝ $295.00	Low
1/31/2021	Oppenheimer	Reiterated Rating	Buy	$266.00	Low
1/19/2021	Morgan Stanley	Boost Target	Overweight	$276.00 ➝ $285.00	Low
1/4/2021	Royal Bank of Canada	Reiterated Rating	Neutral		N/A
12/29/2020	Daiwa Capital Markets	Initiated Coverage	Buy	$300.00 ➝ $300.00	N/A
12/29/2020	Royal Bank of Canada	Reiterated Rating	Neutral		N/A
12/27/2020	Oppenheimer	Initiated Coverage	Positive ➝ Buy	$274.00 ➝ $266.00	N/A
12/27/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A
12/23/2020	Royal Bank of Canada	Reiterated Rating	Neutral		N/A
12/16/2020	Morgan Stanley	Boost Target	Overweight	$275.00 ➝ $276.00	Low
12/15/2020	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Medium
12/9/2020	SVB Leerink	Boost Target	Market Perform	$243.00 ➝ $253.00	Low
12/8/2020	Piper Sandler	Boost Target	Overweight	$270.00 ➝ $280.00	Low
11/16/2020	Oppenheimer	Lower Target	Outperform	$280.00 ➝ $274.00	Low
11/11/2020	Oppenheimer	Initiated Coverage	Positive ➝ Buy	$275.00 ➝ $280.00	Low
11/2/2020	Mizuho	Lower Target	Neutral	$260.00 ➝ $215.00	Low
10/29/2020	Cantor Fitzgerald	Lower Target	Overweight	$279.00 ➝ $278.00	Low
10/29/2020	BMO Capital Markets	Lower Target	Outperform	$308.00 ➝ $304.00	Low
10/29/2020	JPMorgan Chase & Co.	Lower Target	Neutral	$232.00 ➝ $222.00	Medium
10/29/2020	SVB Leerink	Lower Target	Market Perform	$261.00 ➝ $243.00	Medium
10/29/2020	Bank of America	Lower Target	Buy	$275.00 ➝ $265.00	Medium
10/29/2020	Morgan Stanley	Boost Target	Market Perform ➝ Overweight	$273.00 ➝ $275.00	Medium
10/29/2020	Barclays	Lower Target	Equal Weight	$250.00 ➝ $242.00	Low
10/28/2020	UBS Group	Initiated Coverage	Neutral	$232.00	High
10/27/2020	Credit Suisse Group	Lower Target	Outperform	$286.00 ➝ $284.00	Low
10/26/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$255.00	Medium
10/22/2020	Oppenheimer	Lower Target	Outperform	$280.00 ➝ $275.00	Low
10/15/2020	Royal Bank of Canada	Reiterated Rating	Hold	$223.00	Medium
10/13/2020	Morgan Stanley	Lower Target	Overweight	$281.00 ➝ $273.00	Low
10/12/2020	Truist Financial	Upgrade	Hold ➝ Buy		Low
10/9/2020	Truist Financial	Downgrade	Buy ➝ Hold	$251.00	Medium
10/9/2020	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform		Medium
10/6/2020	Raymond James	Reiterated Rating	Outperform ➝ Market Perform		Medium
10/6/2020	Oppenheimer	Boost Target	Positive ➝ Outperform	$270.00 ➝ $280.00	Medium
9/23/2020	William Blair	Reiterated Rating	Hold		Medium
9/22/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
9/21/2020	Oppenheimer	Reiterated Rating	Buy	$270.00	Medium
7/30/2020	SunTrust Banks	Boost Target	Buy	$254.00 ➝ $268.00	Low
7/29/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
7/29/2020	Wells Fargo & Company	Boost Target	Equal Weight ➝ In-Line	$237.00 ➝ $247.00	Low
7/29/2020	Jefferies Financial Group	Boost Target	Buy	$285.00 ➝ $300.00	Low
7/29/2020	Royal Bank of Canada	Lower Target	Sector Perform	$236.00 ➝ $223.00	High
7/29/2020	Morgan Stanley	Lower Target	Overweight	$285.00 ➝ $281.00	Medium
7/29/2020	SVB Leerink	Boost Target	Market Perform	$253.00 ➝ $261.00	Medium
7/29/2020	Cantor Fitzgerald	Boost Target	Overweight	$263.00 ➝ $279.00	Medium
7/29/2020	Barclays	Boost Target	Equal Weight	$245.00 ➝ $250.00	Medium
7/28/2020	Piper Sandler	Boost Target	Positive ➝ Overweight	$255.00 ➝ $270.00	Medium
7/28/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$225.00 ➝ $232.00	Medium
7/20/2020	Oppenheimer	Boost Target	Outperform	$252.00 ➝ $265.00	Low
7/20/2020	Credit Suisse Group	Boost Target	Outperform	$252.00 ➝ $290.00	Low
7/15/2020	Morgan Stanley	Boost Target	Overweight	$280.00 ➝ $285.00	Low
6/18/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$219.00 ➝ $225.00	Medium
6/2/2020	SVB Leerink	Boost Target	Market Perform	$249.00 ➝ $253.00	High
5/4/2020	Cantor Fitzgerald	Boost Target	Overweight	$255.00 ➝ $263.00	Low
5/1/2020	Cfra	Boost Target	Buy	$223.00 ➝ $259.00	Low
5/1/2020	Bank of America	Boost Target	Buy	$250.00 ➝ $265.00	High
5/1/2020	SVB Leerink	Boost Target	Market Perform	$219.00 ➝ $249.00	High
5/1/2020	Morgan Stanley	Boost Target	Overweight	$267.00 ➝ $280.00	High
5/1/2020	BMO Capital Markets	Boost Target	Positive ➝ Outperform	$274.00 ➝ $291.00	High
5/1/2020	Wells Fargo & Company	Boost Target	Equal Weight	$220.00 ➝ $237.00	High
5/1/2020	Oppenheimer	Initiated Coverage	Buy	$252.00	Medium
4/30/2020	Mizuho	Reiterated Rating	Hold	$215.00	Medium
4/30/2020	Piper Sandler	Boost Target	Overweight	$235.00 ➝ $255.00	Medium
4/26/2020	Oppenheimer	Boost Target	Outperform	$240.00 ➝ $250.00	Medium
4/15/2020	Morgan Stanley	Lower Target	Overweight	$277.00 ➝ $267.00	Low
4/15/2020	Guggenheim	Initiated Coverage	Neutral	$225.00	Low
3/31/2020	Wolfe Research	Initiated Coverage	Market Perform	$218.00	Medium
3/29/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$255.00	High
3/26/2020	Oppenheimer	Lower Target	Outperform	$250.00 ➝ $240.00	High
3/13/2020	Cfra	Upgrade	Hold ➝ Buy		High
3/9/2020	Oppenheimer	Lower Target		$256.00 ➝ $250.00	Medium
3/5/2020	Bank of America	Upgrade	Neutral ➝ Buy	$245.00 ➝ $250.00	Medium
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$235.00	High
2/6/2020	Argus	Reiterated Rating	Buy	$265.00 ➝ $265.00	Low
2/3/2020	SunTrust Banks	Boost Target	Buy ➝ Buy	$254.00 ➝ $265.00	Low
2/2/2020	Credit Suisse Group	Reiterated Rating	Buy	$252.00	Low
2/2/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Hold		Low
1/31/2020	Cfra	Boost Target	Hold	$215.00 ➝ $223.00	High
1/31/2020	Cowen	Reiterated Rating	Buy		High
1/31/2020	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$173.00 ➝ $185.00	High
1/30/2020	Mizuho	Reiterated Rating	Hold	$215.00	High
1/24/2020	JPMorgan Chase & Co.	Set Target	Neutral	$198.00	Low
1/23/2020	Citigroup	Boost Target	Buy ➝ In-Line	$245.00 ➝ $275.00	Low
1/22/2020	UBS Group	Boost Target	Neutral	$194.00 ➝ $238.00	Low
1/21/2020	Oppenheimer	Boost Target		$250.00 ➝ $260.00	Low
1/21/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform		Medium
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
1/17/2020	Morgan Stanley	Lower Target	Overweight	$280.00 ➝ $277.00	Low
1/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$255.00	Low
1/9/2020	BMO Capital Markets	Boost Target	Outperform	$240.00 ➝ $275.00	Low
12/23/2019	Raymond James	Initiated Coverage	Market Perform		N/A
12/19/2019	Cowen	Boost Target	Outperform	$253.00 ➝ $277.00	Medium
12/17/2019	Morgan Stanley	Initiated Coverage	Overweight	$280.00	Low
12/13/2019	Credit Suisse Group	Boost Target	Outperform	$235.00 ➝ $250.00	Medium
12/9/2019	Argus	Boost Target	Positive ➝ Buy	$240.00 ➝ $265.00	Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$256.00	Low
11/5/2019	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$230.00 ➝ $255.00	Low
10/30/2019	SVB Leerink	Boost Target	Market Perform	$189.00 ➝ $205.00	High
10/16/2019	Bank of America	Initiated Coverage	Neutral	$215.00	Low
10/14/2019	Sanford C. Bernstein	Initiated Coverage	Outperform		Low
9/30/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
9/30/2019	The Goldman Sachs Group	Set Target	Buy	$243.00	Medium
9/30/2019	BMO Capital Markets	Set Target	Buy	$240.00	Medium
9/30/2019	Cantor Fitzgerald	Set Target	Hold	$230.00	Medium
9/30/2019	SVB Leerink	Set Target	Hold	$189.00	Medium
9/30/2019	Royal Bank of Canada	Reiterated Rating	Hold		Medium
9/29/2019	Cowen	Set Target	Buy	$231.00	Medium
9/29/2019	Mizuho	Reiterated Rating	Hold	$212.00	Medium
9/12/2019	SVB Leerink	Reiterated Rating	Hold		Low
9/9/2019	BMO Capital Markets	Reiterated Rating	Buy		High
9/9/2019	Oppenheimer	Set Target	Buy	$240.00	High
9/6/2019	JPMorgan Chase & Co.	Set Target	Hold	$198.00	High
9/5/2019	Cantor Fitzgerald	Reiterated Rating	Neutral	$221.00 ➝ $230.00	Low
8/30/2019	William Blair	Reiterated Rating	Hold		Medium
8/29/2019	JPMorgan Chase & Co.	Boost Target	Neutral	$191.00 ➝ $198.00	Low
8/27/2019	Oppenheimer	Boost Target		$230.00 ➝ $240.00	Low
8/27/2019	BMO Capital Markets	Boost Target	Outperform	$230.00 ➝ $240.00	Low
8/27/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold	$191.00 ➝ $198.00	Low
8/27/2019	Wells Fargo & Company	Reiterated Rating	Market Perform	$202.00 ➝ $220.00	Low
8/27/2019	Royal Bank of Canada	Boost Target	Sector Perform	$192.00 ➝ $206.00	Low
8/26/2019	Piper Sandler Companies	Boost Target	Overweight	$210.00 ➝ $218.00	Low
8/22/2019	Cowen	Set Target	Buy	$231.00	Low
8/21/2019	Royal Bank of Canada	Boost Target	Sector Perform	$192.00	Low
8/19/2019	Mizuho	Downgrade	Buy ➝ Neutral	$208.00 ➝ $212.00	Low
8/16/2019	Credit Suisse Group	Reiterated Rating	Outperform	$202.00 ➝ $225.00	Low
8/13/2019	Oppenheimer	Boost Target	Outperform	$210.00 ➝ $230.00	Medium
8/12/2019	Citigroup	Reiterated Rating	Buy		Low
8/12/2019	Credit Suisse Group	Set Target	Buy	$202.00	Low
8/12/2019	Wells Fargo & Company	Boost Target	Market Perform ➝ Market Perform	$197.00 ➝ $202.00	High
8/11/2019	Evercore ISI	Reiterated Rating	Hold		High
8/11/2019	Royal Bank of Canada	Reiterated Rating	Hold		High
8/10/2019	Piper Sandler Companies	Set Target	Buy	$210.00	Low
8/9/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
7/31/2019	BMO Capital Markets	Set Target	Buy	$230.00	Low
7/15/2019	Morgan Stanley	Lower Target	Overweight	$211.00 ➝ $207.00	Low
7/1/2019	Mizuho	Reiterated Rating	Buy	$208.00	Low
6/24/2019	Mizuho	Reiterated Rating	Buy	$208.00	Low
5/24/2019	Oppenheimer	Set Target	Buy	$210.00	Medium
5/22/2019	Citigroup	Upgrade	Neutral ➝ Buy	$211.00 ➝ $205.00	Low
5/21/2019	Royal Bank of Canada	Reiterated Rating	Neutral	$192.00	Low
5/20/2019	Credit Suisse Group	Initiated Coverage	Outperform	$208.00 ➝ $208.00	Low
5/17/2019	Mizuho	Reiterated Rating	Buy	$208.00	Low
5/15/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold	$190.00	Medium
5/10/2019	Mizuho	Set Target	Buy	$208.00	High
5/1/2019	Cowen	Reiterated Rating	Buy	$229.00	High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

42 very positive mentions
45 positive mentions
6 negative mentions
2 very negative mentions

Mentions as of

9/28/2023

32 very positive mentions
45 positive mentions
8 negative mentions
4 very negative mentions

Mentions as of

10/28/2023

24 very positive mentions
47 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

11/27/2023

42 very positive mentions
42 positive mentions
4 negative mentions
5 very negative mentions

Mentions as of

12/27/2023

50 very positive mentions
26 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

1/26/2024

41 very positive mentions
54 positive mentions
12 negative mentions
4 very negative mentions

Mentions as of

2/25/2024

48 very positive mentions
47 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/26/2024

42 very positive mentions
23 positive mentions
9 negative mentions
1 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $269.38

$267.24

$274.35

50 Day Range

MA: $275.38

$262.75

$289.18

52 Week Range

Now: $269.38

$211.71

$329.72

Volume

1,792,738 shs

Average Volume

2,827,451 shs

Market Capitalization

$144.49 billion

P/E Ratio

21.57

Dividend Yield

3.29%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Amgen?: The following Wall Street research analysts have issued reports on Amgen in the last year: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for AMGN.
What is the current price target for Amgen?: 21 Wall Street analysts have set twelve-month price targets for Amgen in the last year. Their average twelve-month price target is $296.95, suggesting a possible upside of 10.2%. TD Cowen has the highest price target set, predicting AMGN will reach $360.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $200.00 for Amgen in the next year.
View the latest price targets for AMGN.
What is the current consensus analyst rating for Amgen?: Amgen currently has 9 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMGN.
What other companies compete with Amgen?: Other companies that are similar to Amgen include Gilead Sciences, Seagen, Moderna, Pfizer and Intuitive Surgical. Learn More about companies similar to Amgen.
How do I contact Amgen's investor relations team?: Amgen's physical mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company's listed phone number is (805) 447-1000 and its investor relations email address is [email protected]. The official website for Amgen is www.amgen.com. Learn More about contacing Amgen investor relations.

Amgen - AMGN Stock Price Target and Predictions

Analyst Price Target for AMGN

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.81 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Amgen?

What is the current price target for Amgen?

What is the current consensus analyst rating for Amgen?

What other companies compete with Amgen?

How do I contact Amgen's investor relations team?